CoChat

Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age

Chlibek, R., Bayas, J. M., Collins, H., de la Pinta, M. L. R., Ledent, E., Mols, J. F., Heineman, T. C. · 2013 · Journal of Infectious Diseases

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

BACKGROUND: An adjuvanted varicella-zoster virus glycoprotein E (gE) subunit vaccine candidate for herpes zoster is in development. In this trial we compared the safety, reactogenicity, and immunogenicity of the vaccine antigen combined with different adjuvant doses. METHODS: This was a phase II, observer-blind, randomized, multinational study. Adults ≥50 years old were randomized 4:4:2:1 to be vaccinated at months 0 and 2 with gE combined with a higher (AS01B) or lower (AS01E) dose adjuvant, unadjuvanted gE, or saline. Following each dose, solicited events were recorded for 7 days and unsolicited adverse events for 30 days. Serious adverse events were collected for 1 year. Cell-mediated and humoral immune responses were assessed at baseline and following each dose. RESULTS: No vaccine-related severe adverse events were reported. Solicited adverse events were generally mild to moderate and transient. For all gE-based vaccines, pain was the most common local symptom and fatigue the most common general symptom. Immune responses were significantly enhanced by AS01B and AS01E compared to unadjuvanted gE and were significantly stronger for gE/AS01B than for gE/AS01E. CONCLUSIONS: AS01 improved the immunogenicity of gE while retaining acceptable safety and reactogenicity profiles. The enhancement of gE-specific cellular and humoral responses was adjuvant dose dependent. CLINICAL TRIALS REGISTRATION: NCT00802464.

Overview

Integrity signals

Registry

Crossref · 10.1093/infdis/jit365

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 2

  1. 2012, Vaccine, 31, 2196
  2. Chapman, 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 57, 1

Cited by

See all 149

Metadata

Authors
Chlibek, R., Bayas, J. M., Collins, H., de la Pinta, M. L. R., Ledent, E., Mols, J. F., & Heineman, T. C.
Affiliations
  • Hospital Clínic de Barcelona (ES)
  • GlaxoSmithKline (Belgium) (BE)
  • GlaxoSmithKline (United States) (US)
Venue
Journal of Infectious Diseases
Published
2013-07-31
Volume
208
Issue
12
Pages
1953-1961
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2145061830
Cited by
149
References
22
Citations by year
2026: 6 · 2025: 15 · 2024: 14 · 2023: 6 · 2022: 8 · 2021: 15 · 2020: 9 · 2019: 17 · 2018: 16 · 2017: 15 · 2016: 13 · 2015: 11 · 2014: 4
FWCI
6.80
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
Keywords
herpes zoster, varicella-zoster virus, glycoprotein E, subunit vaccine, AS01 adjuvant, vaccine safety, reactogenicity, immunogenicity, older adults, cell-mediated immunity, humoral immune response
MeSH terms
Adjuvants, Immunologic, Aged, Antibodies, Viral, Female, Herpes Zoster, Humans, Male, Middle Aged, Herpesvirus 3, Human, Viral Envelope Proteins, CD4-Positive T-Lymphocytes, CD4 Lymphocyte Count, Vaccines, Subunit, Herpes Zoster Vaccine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age. https://app.cochat.ai/papers/10.1093/infdis/jit365
The paper
Chlibek, R., Bayas, J. M., Collins, H., de la Pinta, M. L. R., Ledent, E., Mols, J. F., & Heineman, T. C. (2013). Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age. Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jit365

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.